About: IMPORTANCE: New York City is a global epicenter for the SARS-CoV-2 outbreak with a significant number of individuals infected by the virus. Patients with multiple myeloma have a compromised immune system, due to both the disease and anti-myeloma therapies, and may therefore be particularly susceptible to coronavirus disease 2019 (COVID-19); however, there is limited information to guide clinical management. OBJECTIVE: To assess risk factors and outcomes of COVID-19 in patients with multiple myeloma. DESIGN: Case-series. SETTING: Five large academic centers in New York City. PARTICIPANTS: Patients with multiple myeloma and related plasma cell disorders who were diagnosed with COVID-19 between March 10(th), 2020 and April 30(th,) 2020. EXPOSURES: Clinical features and risk factors were analyzed in relation to severity of COVID-19. MAIN OUTCOMES AND MEASURES: Descriptive statistics as well as logistic regression were used to estimate disease severity reflected in hospital admissions, intensive care unit (ICU) admission, need for mechanical ventilation, or death. RESULTS: Of 100 multiple myeloma patients (male 58%; median age 68, range 41–91) diagnosed with COVID-19, 74 (74%) were admitted; of these 13 (18%) patients were placed on mechanical ventilation, and 18 patients (24%) expired. None of the studied risk factors were significantly associated (P>0.05) with adverse outcomes (ICU-admission, mechanical ventilation, or death): hypertension (N=56) odds ratio (OR) 2.3 (95% confidence interval [CI] 0.9–5.9); diabetes (N=18) OR 1.1 (95% CI 0.3–3.2); age >65 years (N=63) OR 2.0 (95% CI 0.8–5.3); high dose melphalan with autologous stem cell transplant <12 months (N=7) OR 1.2 (95% CI 0.2–7.4), IgG<650 mg/dL (N=42) OR=1.2 (95% CI 0.4–3.1). In the entire series of 127 patients with plasma cell disorders, hypertension was significantly associated with the combined end-point (OR 3.4, 95% CI 1.5–8.1). CONCLUSIONS AND RELEVANCE: Although multiple myeloma patients have a compromised immune system due to both the disease and therapy; in this largest disease specific cohort to date of patients with multiple myeloma and COVID-19, compared to the general population, we found risk factors for adverse outcome to be shared and mortality rates to be within the higher range of officially reported mortality rates.   Goto Sponge  NotDistinct  Permalink

An Entity of Type : fabio:Abstract, within Data Space : wasabi.inria.fr associated with source document(s)

AttributesValues
type
value
  • IMPORTANCE: New York City is a global epicenter for the SARS-CoV-2 outbreak with a significant number of individuals infected by the virus. Patients with multiple myeloma have a compromised immune system, due to both the disease and anti-myeloma therapies, and may therefore be particularly susceptible to coronavirus disease 2019 (COVID-19); however, there is limited information to guide clinical management. OBJECTIVE: To assess risk factors and outcomes of COVID-19 in patients with multiple myeloma. DESIGN: Case-series. SETTING: Five large academic centers in New York City. PARTICIPANTS: Patients with multiple myeloma and related plasma cell disorders who were diagnosed with COVID-19 between March 10(th), 2020 and April 30(th,) 2020. EXPOSURES: Clinical features and risk factors were analyzed in relation to severity of COVID-19. MAIN OUTCOMES AND MEASURES: Descriptive statistics as well as logistic regression were used to estimate disease severity reflected in hospital admissions, intensive care unit (ICU) admission, need for mechanical ventilation, or death. RESULTS: Of 100 multiple myeloma patients (male 58%; median age 68, range 41–91) diagnosed with COVID-19, 74 (74%) were admitted; of these 13 (18%) patients were placed on mechanical ventilation, and 18 patients (24%) expired. None of the studied risk factors were significantly associated (P>0.05) with adverse outcomes (ICU-admission, mechanical ventilation, or death): hypertension (N=56) odds ratio (OR) 2.3 (95% confidence interval [CI] 0.9–5.9); diabetes (N=18) OR 1.1 (95% CI 0.3–3.2); age >65 years (N=63) OR 2.0 (95% CI 0.8–5.3); high dose melphalan with autologous stem cell transplant <12 months (N=7) OR 1.2 (95% CI 0.2–7.4), IgG<650 mg/dL (N=42) OR=1.2 (95% CI 0.4–3.1). In the entire series of 127 patients with plasma cell disorders, hypertension was significantly associated with the combined end-point (OR 3.4, 95% CI 1.5–8.1). CONCLUSIONS AND RELEVANCE: Although multiple myeloma patients have a compromised immune system due to both the disease and therapy; in this largest disease specific cohort to date of patients with multiple myeloma and COVID-19, compared to the general population, we found risk factors for adverse outcome to be shared and mortality rates to be within the higher range of officially reported mortality rates.
Subject
  • Virology
  • Safety engineering
  • Populated places established in 1898
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software